Innovation does not happen in a vacuum. Instead, it requires a rich ecosystem of talent, capital, expertise and logistics to translate theoretical science into life-saving treatments and therapies. Supportive policies also help encourage investment, as well as provide strong IP protections that promote long-term strategic planning.
Such an environment is the result of intentional cooperation among government, research institutions and biopharmaceutical companies. A great example is Massachusetts. Home to one of the world’s most vibrant hubs for the biopharmaceutical and life science industries, the Bay State is a consistent source of innovation that fosters far-reaching economic and scientific benefits.